How to manage traumatic optic neuropathy?  by Wang, An-Guor
lable at ScienceDirect
Taiwan Journal of Ophthalmology 5 (2015) 1e2Contents lists avaiTaiwan Journal of Ophthalmology
journal homepage: www.e-t jo.comEditorialHow to manage traumatic optic neuropathy?In this issue of the Taiwan Journal of Ophthalmology, a review
article on traumatic optic neuropathy by Dr Patrick Yu-Wai-Man1
is included. The article reviews the clinical features and current ev-
idence of treatment for traumatic optic neuropathy. The contro-
versy surrounding the use of steroid in the management of
traumatic optic neuropathy has been a matter of debate over a
long period. Dr Patrick Yu-Wai-Man1 has reviewed the background
and rationale for the use of steroids and surgical decompression.
Recent evidence of the beneﬁt and disadvantage in each therapy
has been described as well.
1. Treatment options for traumatic optic neuropathy
There are several options for the treatment of traumatic optic
neuropathy, with steroid use and surgical decompression of the op-
tic canal being the two main therapeutic modalities. Both of these
modalities aim to decrease the optic nerve pressure within the op-
tic canal because the main pathogenic mechanism hypothesizes
that trauma-induced edema within the bony conﬁnes of the optic
canal may further compromise the vascular supply of the optic
nerve and cause secondary neuronal cell death.1 Thus, decreasing
optic nerve edema by steroid use or removing the bony conﬁnes
of the optic canal by surgical procedure may help prevent second-
ary cell loss. In addition to these two treatment modalities, many
doctors now adopt a conservative strategy such as clinical observa-
tion, because there is a high percentage of spontaneous recovery
following traumatic optic neuropathy.2
2. Rationale for steroid treatment
As Dr Patrick Yu-Wai-Man1 mentions in his review article, the
use of steroid has become a popular choice for the treatment of
traumatic optic neuropathy after the 1980s because of the success-
ful use of steroids in the second National Acute Spinal Cord Injury
Study (NASCIS II).3 The NASCIS II was a multicenter, randomized,
double-blind, prospective clinical trial conducted in 1990, and itshttp://dx.doi.org/10.1016/j.tjo.2015.01.002
2211-5056/Copyright © 2015, The Ophthalmologic Society of Taiwan. Published by Elsevresults showed that patients receiving amegadose of steroid (initial
dose, 30 mg/kg, then 5.4 mg/kg/h for 23 hours) within 8 hours of
spinal injury may have better neurological functions and less resid-
ual sequelae. In the next trial (i.e., NASCIS III), the authors reported
an even better outcome of motor function if the treatment lasts for
48 hours instead of 24 hours.4 Traditional use of steroids (high dose,
1000 mg/d for 3 days) may reduce edema and anti-inﬂammation.
When administered in megadoses, steroids are proposed to have
an additional neuroprotective effect through the mechanism of
reducing oxidative stress and decreasing reactive oxygen species.
3. Changing trend in steroid use
In the UK surveillance of traumatic optic neuropathy, Lee et al5
found a total of 116 cases of traumatic optic neuropathy from 2004
to 2006. Only 41 (35%) of these 116 patients received steroid treat-
ment, whereas the remaining 75 (65%) patients received clinical
observation alone.5 This implies that there is a trend toward
more conservative treatment for traumatic optic neuropathy. This
changing trend may result from the following evidence.
3.1. Applicability of the NASCIS II
Although administration of steroids in megadoses has been
proved to have a neuroprotective effect on the acute spinal cord
injury, it remains uncertain whether it has the same effect in optic
nerve injury. The optic nerve is mainly composed of axons from
retinal ganglion cells intermixed with glia, vessels, and connective
tissues. Bycontrast, the spinal cordhas graymatter andwhitematter
and it includes motor neurons, interneurons, glia, and motor and
sensory axons. They are different functionally and anatomically.
Thus, extrapolating the successful outcome of NASCIS II to the treat-
ment of traumatic optic neuropathy is not without concern.
In addition, the beneﬁcial effect of megadose steroid is limited
to patients receiving treatment within 8 hours. Patients who
received treatment after 8 hours may have a worse outcome than
the control group.3 Most patients with traumatic optic neuropathy
came for eye care later than 8 hours, because some patients may
have concurrent craniofacial injury or even conscious disturbance
at the initial stage. Thus, the applicability of NASCIS II results to clin-
ical management of traumatic optic neuropathy remains uncertain.
3.2. Absence of large-scale clinical trial
It is difﬁcult to recruit a large number of patients with traumatic
optic neuropathy in a short period. Besides, the clinical condition is
complex as some patients may suffer from concurrent craniofacial
injury or conscious disturbance. It is difﬁcult to assess visualier Taiwan LLC. All rights reserved.
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approximate results are available most of the time. In addition, vi-
sual impairment may vary widely following an optic nerve injury.
With all these limitations, to-date there is no large-scale, random-
ized, double-blind, prospective clinical trial for traumatic optic neu-
ropathy. Only one small-scale, randomized, prospective clinical trial
was found in the Cochrane report by Drs Patrick Yu-Wai-Man and
Grifﬁths.6 In this small trial, Dr Entezari et al7 examined the effect
of high-dose steroid (250 mg/6 h for 3 days, and oral steroid
1 mg/kg/d for 14 days) in 31 patients with traumatic optic neurop-
athy. Therewas no signiﬁcant difference in visual outcome between
patients who received steroid treatment and those who did not.73.3. Increased mortality in patients with combined signiﬁcant head
injury
The use of megadose steroid (initial dose, 2 g, followed by 0.4 g/
h for 48 hours) was found to be associated with a higher mortality
rate (21.1%), compared with the rate in the control group (17.9%), at
2 weeks following signiﬁcant head injury in a large-scale clinical
trialdCorticosteroid Randomization After Signiﬁcant Head Injury.8
This indicates that the megadose steroid use should be avoided in
traumatic optic neuropathy patients with combined severe head
injury.3.4. High spontaneous recovery rate in traumatic optic neuropathy
A high spontaneous recovery rate is observed in patients with
traumatic optic neuropathy.2 This evidence supports conservative
management of clinical observation to obviate potential complica-
tions arising from steroid use and surgical decompression.
4. How to manage traumatic optic neuropathy?
With no obvious advantage from any treatments,1,2,9e12 clinical
doctors may choose their favorable way of management. Dr Volpe
and Dr Levin12 presented an in-depth discussion of this speciﬁc
issue in the Journal of Neuro-Ophthalmology in 2011. The current
strategy to manage patients with traumatic optic neuropathy is
suggested as follows.
Patients with traumatic optic neuropathy may choose to receive
steroids, surgical decompression, or clinical observation. The
beneﬁt of surgical decompression for traumatic optic neuropathy
remains obscure,2,9 partly because visual outcome greatly varies
depending on surgeon's experience and technique level. In each
hospital, whether eye doctors choose to recommend surgical
decompression or not mainly depends on if they have available
expertise. Clinical observation is also a good choice because there
is a high spontaneous recovery rate,1,2 and it may avoid the poten-
tial side effects from the steroid and surgery. However, it seems
hardly acceptable to do “clinical observation” alone as the treat-
ment for traumatic visual loss, especially in the local health care
culture here (Taiwan).
With regard to the use of steroid treatment, it is suggested that
the possible beneﬁts and side effects should be clearly explained to
the patients. Clinical parameters, such as blood sugar and intraoc-
ular pressure, should be carefully monitored during the course of
treatment. The dose of steroid treatment depends on the arrival
time.4.1. Patients arrive within 8 hours after trauma
If they arrive earlier than 8 hours after injury, megadose steroid
may be instituted for the possible beneﬁt of neuroprotection. If
there is any sign of associated craniofacial injury, the neurosurgical
department should be consulted ﬁrst. There are several conditions
unsuitable for the megadose use, for example, concurrent severe
head injury, conscious disturbance, inability to assess visual func-
tion, or severe eyeball injury. For these complicated conditions,
traditional high-dose steroid would be a better choice.4.2. Patients arrive later than 8 hours after trauma
If the patient arrives later than 8 hours following injury, tradi-
tional high-dose steroid is suggested. High-dose steroid has the ef-
fect of reducing tissue edema and anti-inﬂammation, and most
importantly, with a reasonable risk of drug-related side effects.References
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